Trials / Completed
CompletedNCT01135368
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 506 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.
Detailed description
Lansoprazole is currently approved in Germany for the treatment of erosive reflux esophagitis and active duodenal and gastric ulcer disease, and for long-term treatment including maintenance of healed reflux esophagitis and duodenal ulcer disease and treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome. This study was conducted to evaluate the safety, efficacy and quality of life of patients receiving up to five years of treatment with lansoprazole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lansoprazole | Lansoprazole capsules |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2010-06-02
- Last updated
- 2012-09-03
- Results posted
- 2012-09-03
Source: ClinicalTrials.gov record NCT01135368. Inclusion in this directory is not an endorsement.